A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Rizos, Emmanouil ^a   Papathanasiou, Matilda A ^a   Michalopoulou, Panagiota G ^a,b   Laskos, Efstathios ^d   Mazioti, Aggeliki ^a   Kastania, Anastasia ^c   Vasilopoulou, Konstantina ^a   Nikolaidou, Paraskevi ^a   Margaritis, Dimitrios ^a   Papageorgiou, Charalabos ^a   Liappas, Ioannis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ATHENS UNIVERSITY OF ECONOMICS AND BUSINESS   (Greece)

^d Athens Psychiatric Hospital Dromokaition   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HUMAN; LEFT HEMISPHERE; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; TIME TO TREATMENT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; SCHIZOPHRENIA;

EID: 84895803387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087997     Document Type: Article

References (66)

1. Angelucci F, Brene S, Mathe AA (2005) BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 10: 345-352.
2. Buckley PF, Mahadik S, Pillai A, Terry A, Jr. (2007) Neurotrophins and schizophrenia. Schizophr Res 94: 1-11. (Pubitemid 47033973)
3. Buckley PF, Pillai A, Howell KR (2011) Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 24: 122-127.
4. Nieto R, Kukuljan M, Silva H (2013) BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry 4: 45.
5. Rizos EN, Papathanasiou M, Michalopoulou PG, Mazioti A, Douzenis A, et al. (2011) Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophr Res 129: 201-204.
6. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, et al. (2010) Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 11: 251-255.
7. Angelucci F, Mathe AA, Aloe L (2000) Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 60: 783-794. (Pubitemid 30399550)
8. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, et al. (2007) Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41: 31-35. (Pubitemid 44708213)
9. Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, et al. (2011) Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 491: 207-210.
10. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY (2005) Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382: 27-32.
11. Pirildar S, Gonul AS, Taneli F, Akdeniz F (2004) Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 28: 709-713. (Pubitemid 38987396)
12. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, et al. (2007) Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4- hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31: 1072-1077. (Pubitemid 46810098)
13. Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, et al. (2007) Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22: 21-27. (Pubitemid 44950764)
14. Pillai A, Terry AV, Jr., Mahadik SP (2006) Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 82: 95-106. (Pubitemid 43202652)
15. Chen CC, Huang TL (2011) Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 189: 327-330.
16. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, et al. (2007) Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 420: 45-48. (Pubitemid 46777098)
17. Tamminga CA, Stan AD, Wagner AD (2010) The hippocampal formation in schizophrenia. Am J Psychiatry 167: 1178-1193.
18. Boyer P, Phillips JL, Rousseau FL, Ilivitsky S (2007) Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Brain Res Rev 54: 92-112. (Pubitemid 46509660)
19. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, et al. (2011) Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res 131: 165-173.
20. Shenton ME, Gerig G, McCarley RW, Szekely G, Kikinis R (2002) Amygdala-hippocampal shape differences in schizophrenia: the application of 3D shape models to volumetric MR data. Psychiatry Res 115: 15-35. (Pubitemid 34880096)
21. Nelson MD, Saykin AJ, Flashman LA, Riordan HJ (1998) Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 55: 433-440. (Pubitemid 28237277)
22. Adriano F, Caltagirone C, Spalletta G (2012) Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 18: 180-200.
23. Verma S, Sitoh YY, Ho YC, Poon LY, Subramaniam M, et al. (2009) Hippocampal volumes in first-episode psychosis. J Neuropsychiatry Clin Neurosci 21: 24-29.
24. Hohn A, Leibrock J, Bailey K, Barde YA (1990) Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 344: 339-341.
25. Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C (2006) BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns 6: 941-951. (Pubitemid 44309446)
26. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, et al. (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63: 139-149. (Pubitemid 43213875)
27. Mamah D, Harms MP, Barch D, Styner M, Lieberman JA, et al. (2012) Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Front Psychiatry 3: 96.
28. Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, et al. (2011) Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol 14: 69-82.
29. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA (2006) Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 188: 510-518. (Pubitemid 43844097)
30. Meisenzahl EM, Koutsouleris N, Bottlender R, Scheuerecker J, Jager M, et al. (2008) Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophr Res 104: 44-60.
31. Davidson CA, Kuroki N, Alvarado JL, Niznikiewicz MA, McCarley RW, et al. (2012) An MRI study of septi pellucidi in relation to hippocampus volume and fornix integrity in schizophrenia. Schizophr Res 134: 165-170.
32. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, et al. (1997) Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res 74: 129-140. (Pubitemid 27315863)
33. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68: 128-137.
34. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667.
35. Cook MJ, Fish DR, Shorvon SD, Straughan K, Stevens JM (1992) Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 115 (Pt 4): 1001-1015.
36. Free SL, Bergin PS, Fish DR, Cook MJ, Shorvon SD, et al. (1995) Methods for normalization of hippocampal volumes measured with MR. AJNR Am J Neuroradiol 16: 637-643.
37. SPSS I Bootstrap 20 User's Guide.
38. ACD DVH (2006) Bootstrap Methods and their Application.
39. R.Alessandra B, Davidson CA (2008) Accurate Parametric Inference for Small Samples. Statistical Science 23: 465-484.
40. Colibazzi T, Wexler BE, Bansal R, Hao X, Liu J, et al. (2013) Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. PLoS One 8: e55783.
41. Vita A, De Peri L, Deste G, Sacchetti E (2012) Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry 2: e190.
42. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, et al. (1994) Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 151: 1430-1436. (Pubitemid 24301686)
43. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, et al. (2001) Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 49: 487-499. (Pubitemid 32226407)
44. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, et al. (2005) Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62: 361-370. (Pubitemid 40471685)
45. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, et al. (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60: 358-403.
46. Wakade CG, Mahadik SP, Waller JL, Chiu FC (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69: 72-79. (Pubitemid 34734166)
47. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM (2003) Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71: 127-131. (Pubitemid 36008409)
48. Siekmeier PJ, vanMaanen DP (2013) Development of antipsychotic medications with novel mechanisms of action based on computational modeling of hippocampal neuropathology. PLoS One 8: e58607.
49. Koolschijn PC, van Haren NE, Cahn W, Schnack HG, Janssen J, et al. (2010) Hippocampal volume change in schizophrenia. J Clin Psychiatry 71: 737-744.
50. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, et al. (2005) Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 186: 26-31. (Pubitemid 40070540)
51. McClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, et al. (2006) Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res 148: 121-132. (Pubitemid 44750583)
52. Panenka WJ, Khorram B, Barr AM, Smith GN, Lang DJ, et al. (2007) A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia. Schizophr Res 94: 288-292. (Pubitemid 47031604)
53. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, et al. (2006) Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 86: 321-322. (Pubitemid 44234056)
54. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, et al. (2007) Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res 41: 997-1004. (Pubitemid 47304448)
55. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, et al. (2008) Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1308-1311.
56. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, et al. (2009) Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 33: 1508-1512.
57. Reis HJ, Nicolato R, Barbosa IG, Teixeira do Prado PH, Romano-Silva MA, et al. (2008) Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett 439: 157-159.
58. Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, et al. (2003) Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351: 111-114. (Pubitemid 37329601)
59. Huang TL, Lee CT (2006) Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 40: 664-668.
60. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, et al. (2009) Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 66: 549-553.
61. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, et al. (2008) BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 33: 2200-2205. (Pubitemid 351992089)
62. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561. (Pubitemid 28550429)
63. Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328: 261-264. (Pubitemid 34876661)
64. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, et al. (2009) Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 42: 270-276.
65. Yoshida T, Ishikawa M, Iyo M, Hashimoto K (2012) Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF) and Its Precursor proBDNF in Healthy Subjects. Open Clin Chem J 5: 7-12.
66. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, et al (2012) Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder. PLoS One 7: e42676.